ライフサイエンスコーパス: anti-angiogenic

1 Sulf1 has been recently recognized to be anti-angiogenic.

2 (165) stimulates angiogenesis, VEGF(165)b is anti-angiogenic.

3 its immunomodulatory, anti-proliferative and anti-angiogenic actions, was effective in improving BCVA

4 erived factor, PEDF, which is known to exert anti-angiogenic actions.

5 e (AM) anti-inflammatory, anti-scarring, and anti-angiogenic actions.

6 helper T cell (TH1) immune stimulation, and anti-angiogenic activities.

7 assumed to be the receptor that mediates its anti-angiogenic activities.

8 cycle arrest and with both proapoptotic and anti-angiogenic activities.

9 chemokine (or platelet factor 4) with potent anti-angiogenic activity and differed only in three amin

10 Cleavage of CgA by thrombin abrogated its anti-angiogenic activity and generated fragments (lackin

11 bled into core/shell nanodrugs with combined anti-angiogenic activity and significantly reduced antic

12 AI-1, rPAI-1(23), that possesses significant anti-angiogenic activity and stimulates high levels of a

13 ProAgio also has anti-angiogenic activity and strongly inhibits growth of

14 Aspergillus fumigatus that is known for its anti-angiogenic activity by binding to human methionine

15 irectly involved in the microenvironment and anti-angiogenic activity in NPC development.

16 cells (designated EDM-TTF-1(+)) displayed an anti-angiogenic activity in the endothelial cell tube fo

17 amily members have been shown to have potent anti-angiogenic activity in vivo.

18 The anti-angiogenic activity of A-LHU was investigated both

19 alternative helix conformation enhances the anti-angiogenic activity of CXCL4L1 by reducing the glyc

20 We propose that ferritin blocks the anti-angiogenic activity of HKa by reducing binding of H

21 de a mechanistic basis for understanding the anti-angiogenic activity of semaphorin as well as the ph

22 cently, we discovered that opticin possesses anti-angiogenic activity using a murine oxygen-induced r

23 ons, agonism/antagonism of GPCR ligands, and anti-angiogenic activity.

24 Ferritin binds to HKa and blocks its anti-angiogenic activity.

25 esting that anti-CLEC14A antibodies may have anti-angiogenic activity.

26 oma blood vessels, consistent with its known anti-angiogenic activity.

27 n 5 (D5) both have been shown to have potent anti-angiogenic activity.

28 angiogenesis assay, sorafenib showed potent anti-angiogenic activity.

29 ective Stat3 inhibitor, on IFNalpha-mediated anti-angiogenic activity.

30 iomolybdate (TM) is a potent anti-cancer and anti-angiogenic agent and has been investigated in a num

31 cated by the recent development of the novel anti-angiogenic agent bevacizumab (Avastin).

32 on is associated with a poor response to the anti-angiogenic agent bevacizumab in patients with color

33 ty acid (SCFA), acts classically as a potent anti-angiogenic agent in tumour angiogenesis models, som

34 However, the effectiveness of this anti-angiogenic agent is limited by the presence of inna

35 se) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF recepto

36 The anti-angiogenic agent, diamino propane tetraiodothyroace

37 elial growth factor and acts primarily as an anti-angiogenic agent.

38 ns as low as 5 muM, rendering it a promising anti-angiogenic agent.

39 ges the study of polymeric nanoparticles and anti-angiogenic agents and offers new insight for the ra

40 may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.

41 may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.Oncogene advanc

42 inoma that was treated with two FDA-approved anti-angiogenic agents at clinically relevant dosages.

43 e development of novel, molecularly targeted anti-angiogenic agents for breast cancer therapies.

44 However, anti-angiogenic agents have only had modest therapeutic

45 in part explain the preferential effects of anti-angiogenic agents in older GBM and pave the way to

46 emonstrated the anti-tumor effects of varied anti-angiogenic agents in sarcoma cell lines and tumor m

47 tumors with microsatellite instability, and anti-angiogenic agents may be used in combination with o

48 The model also shows a response to anti-angiogenic agents similar to previously described i

49 We tested sunitinib and sorafenib, two oral anti-angiogenic agents that are effective in advanced re

50 heir mechanism of action: VEGF inhibitors or anti-angiogenic agents, EGFR inhibitors, mTOR inhibitors

51 We propose the use of anti-angiogenic agents, now being used in cancer regimen

52 o-angiogenic factors and inducing endogenous anti-angiogenic agents.

53 ffers new insight for the rational design of anti-angiogenic agents.

54 er, our data suggest that PCBs act as potent anti-angiogenic agents.

55 medicated with bisphosphonate, denosumab or anti-angiogenic agents.

56 bition or fat-targeted knockdown of NPY2R is anti-angiogenic and anti-adipogenic, while reducing abdo

57 number of pharmacologic benefits, including anti-angiogenic and anti-inflammatory properties.

58 ginex is a synthetic beta-sheet peptide with anti-angiogenic and anti-tumor activity.

59 CXCL4L1 is a highly potent anti-angiogenic and anti-tumor chemokine, and its struct

60 ding properties and to an enhancement of its anti-angiogenic and anti-tumor effects.

61 be pivotal in the mechanism underpinning its anti-angiogenic and anti-tumorigenic activities.

62 ptor that has been studied primarily for its anti-angiogenic and anti-tumorigenic properties.

63 This is the first report that ADAMTS5 is an anti-angiogenic and anti-tumorigenic protein independent

64 These results identify important anti-angiogenic and anti-tumorigenic roles for PPARalpha

65 This anti-angiogenic and anti-tumour effect is more robust th

66 nucleus to the cytoplasm could be useful in anti-angiogenic and breast cancer therapies.

67 mpact of different scheduling strategies for anti-angiogenic and cytotoxic agents (either in monother

68 mer in the extracellular matrix; it has both anti-angiogenic and immunosuppressive properties.

69 etastatic miRNA network, identify ApoE as an anti-angiogenic and metastasis-suppressive factor, and u

70 hat the VEGFR2/AMPK/PEG3 axis integrates the anti-angiogenic and pro-autophagic bioactivities of deco

71 Anti-angiogenic and vascular disrupting therapies rely o

72 ngiogenesis and represent a novel target for anti-angiogenic and vascular normalization therapies.

73 els of forms of full-length CgA and CgA1-76 (anti-angiogenic) and lower levels of fragments lacking t

74 EGF-GemC18-NPs were more anti-proliferative, anti-angiogenic, and pro-apoptotic.

75 uestion whether netrin-4 acts either pro- or anti-angiogenic, angiogenesis in the retina was assessed

76 unreported mechanism of action of TRC105, an anti-angiogenic anti-Endoglin antibody currently evaluat

77 The identification of anti-angiogenic/anti-tumorigenic properties of PPARalpha

78 phosphoinositide recycling provides a useful anti-angiogenic approach.

79 al growth factor (VEGF), the main target for anti-angiogenic-based therapies, and interleukin-8 (IL-8

80 FKBPL may be a useful anti-angiogenic biomarker in CVD in the absence of diabe

81 igh-VEGF tumors may be most likely to escape anti-angiogenics by upregulating VEGF, driving CSC self-

82 d agents are currently in clinical trials as anti-angiogenic cancer therapeutics.

83 s, identifying NG2 as a potential target for anti-angiogenic cancer therapy.

84 the NFkappaB pathway, in turn triggering an anti-angiogenic cascade, might inhibit tumorigenesis and

85 eutic substances, including neurotrophic and anti-angiogenic compounds or protein based biosimilars.

86 tion inhibitors, stem-cell targeted therapy, anti-angiogenic compounds, vaccines and immunomodulating

87 also be used to test the efficacy of pro-and anti-angiogenic compounds.

88 steal AML cells produce pro-inflammatory and anti-angiogenic cytokines and gradually degrade endostea

89 We have shown that the soluble anti-angiogenic domain of BAI1 (termed Vstat120) require

90 pected opportunity to repurpose axitinib, an anti-angiogenic drug approved for renal cancer, as an in

91 Here, the anti-angiogenic drug quininib was formulated into hyalur

92 ions posits new mechanisms for understanding anti-angiogenic drug resistance and presents an expanded

93 a-null tumors were sensitive to the targeted anti-angiogenic drug sunitinib but resistant to cytotoxi

94 While the anti-angiogenic drug thalidomide inhibits HIF-1-dependen

95 ring of tumor vascularity in response to the anti-angiogenic drug tivozanib.

96 Bevacizumab, an anti-angiogenic drug, added to standard chemotherapy dem

97 Promising anti-angiogenic drugs are currently available; however,

98 Introduction of anti-angiogenic drugs targeting vascular endothelial gro

99 A comparison of the clinical efficacy of anti-angiogenic drugs with their corresponding preclinic

100 f AMD can be treated to varying degrees with anti-angiogenic drugs, but geographic atrophy (GA) is an

101 to understanding angiogenesis and developing anti-angiogenic drugs, but most work only involves numer

102 Interestingly, anti-angiogenic drugs, such as bevacizumab, when used at

103 in the tumor growth accompanied by a higher anti-angiogenic effect compared to the free bevacizumab.

104 nsaturated fatty acids (PUFAs) have a highly anti-angiogenic effect in animal models.

105 d squamous NPC HK1 cells, but also showed an anti-angiogenic effect in the animal assay, revealing a

106 The anti-angiogenic effect of antagomir-132 was reflected by

107 This study is the first to demonstrate the anti-angiogenic effect of CLA in the brain, and suggests

108 reduction in blood vessel density due to the anti-angiogenic effect of dexamethasone.

109 The potent anti-angiogenic effect of miR-192 stems from its ability

110 endothelial and tumorigenic properties, the anti-angiogenic effect of PSP-2 might potentially transl

111 To test the anti-angiogenic effect of PSP-2, a recently developed hi

112 been used to investigate the anti-tumor and anti-angiogenic effect of SFN.

113 We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microva

114 This anti-angiogenic effect was prevented by administration o

115 GBM xenograft tumors and displayed a strong anti-angiogenic effect, suggesting dual cancer fighting

116 umor size, in cytokeratin-7+ cells and by an anti-angiogenic effect.

117 angiogenic factors, resulting in an enhanced anti-angiogenic effect.

118 However, the mechanisms by which PCBs cause anti-angiogenic effects are unclear.

119 vating the Notch/Dll pathway and by inducing anti-angiogenic effects at the maternal-fetal interface.

120 Ets-1 not only rescued miR-199a-5p-dependent anti-angiogenic effects but also reversed miR-199a-5p-in

121 elated metalloprotease ADAMTS1, which exerts anti-angiogenic effects by cleavage of thrombospondins a

122 Here, we evaluated PCB-mediated anti-angiogenic effects by diverse but complementary app

123 omato fruit (TCMPs) have been shown to exert anti-angiogenic effects by inhibiting endothelial cell m

124 type 2 diabetes therapy, is associated with anti-angiogenic effects in conditions beyond diabetes.

125 alization in fibrosis might have detrimental anti-angiogenic effects leading to aggravated peritubula

126 We show that the anti-angiogenic effects of endorepellin cannot occur in

127 udy was to evaluate the in vitro and in vivo anti-angiogenic effects of ERbeta selective agonist, bet

128 8 MAPK as blocking its activity restored the anti-angiogenic effects of IGFBP-4 on VEGF-induced blood

129 ying mechanism for the anti-inflammatory and anti-angiogenic effects of SERPINA3K.

130 in vitro studies have reported both pro- and anti-angiogenic effects of Slits.

131 artner for TM601 is also consistent with the anti-angiogenic effects of TM601.

132 hanism of miR-21 mediating metformin-induced anti-angiogenic effects, providing important implication

133 l cycle arrest at the G1-S phase and elicits anti-angiogenic effects.

134 ctly targets FGF2 and VEGF to facilitate its anti-angiogenic effects.

135 velopment of this peptidomimetic and for its anti-angiogenic effects.

136 growth over time by bioluminescence and the anti-angiogenic effects.

137 signaling in endothelial cells, with potent anti-angiogenic effects.

138 This anti-angiogenic environment is accompanied by subclinica

139 Finally, murine endoglin ECD-Fc acted as an anti-angiogenic factor that decreased blood vessel sprou

140 trol, evMDSC have increased expression of an anti-angiogenic factor thrombospondin 1 (Tsp-1) and decr

141 stigated the effect of miR200-b, a potential anti-angiogenic factor, on VEGF receptor 2 (VEGFR-2) exp

142 or cells is the repression of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

143 s supporting Netrin-4 as either a pro- or an anti-angiogenic factor.

144 ic cytokine IL-8 and increased levels of the anti-angiogenic factors activin-A and pigment epithelium

145 ein expression of several pro-angiogenic and anti-angiogenic factors in response to (1) a single acut

146 kappa opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors.

147 to release of proinflammatory cytokines and anti-angiogenic factors into the maternal circulation.

148 clampsia (PE) are primarily driven by excess anti-angiogenic factors originating from the placenta.

149 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic factors whose synthesis is driven by hyp

150 is, including a reset profile of pro- versus anti-angiogenic factors, apparently distinct for physiol

151 1alpha modulated a couple key angiogenic and anti-angiogenic factors, resulting in an enhanced anti-a

152 ion while exhibiting increased expression of anti-angiogenic factors, such as endostatin, and decreas

153 be regulated by the balance between pro- and anti-angiogenic factors.

154 glomerular endotheliosis, and production of anti-angiogenic factors.

155 ombospondin-1 (TSP-1) and its receptor CD36, anti-angiogenic factors.

156 ving as chaperones, hormone transporters, or anti-angiogenic factors.

157 ic asthmatic airways via modulating pro- and anti-angiogenic factors.

158 rom the imbalance between pro-angiogenic and anti-angiogenic factors.

159 altering their secretion of various pro- and anti-angiogenic factors.

160 sted an essential role for PML in IFNalpha's anti-angiogenic function.

161 We have identified anti-angiogenic functions for synthetic double stranded

162 d function of various proteins with pro- and anti-angiogenic functions.

163 ent of Hsa21 in Tc1 mice identified putative anti-angiogenic genes (ADAMTS1and ERG) and novel endothe

164 proliferation through the downregulation of anti-angiogenic genes such as Col4a2, Spry1 and Timp3, w

165 essed genes, non-genomic sequences, pro- and anti-angiogenic genes, and RNAi-incompetent siRNAs all s

166 s driven by changes in expression of several anti-angiogenic genes.

167 This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mo

168 not TSR2 (the C-terminal TSR) of ADAMTS5 is anti-angiogenic in vitro.

169 endothelial growth factor signals, pro- and anti-angiogenic inflammatory chemokine signals, and the

170 The existence of anti-angiogenic isoform (VEGF165b) in PAD muscle tissues

171 itors of SRPK1 switched splicing towards the anti-angiogenic isoform VEGF165b in PC-3 cells and decre

172 using current methods, and demonstrate that anti-angiogenic isoforms are not commonly expressed in m

173 A second set of anti-angiogenic isoforms termed VEGFAxxxb that utilise a

174 iogenic isoforms typified by VEGF-A165a, and anti-angiogenic isoforms typified by VEGF-A165b.

175 network perturbation by three multi-targeted anti-angiogenic kinase inhibitors.

176 lthough, a vast number of pro-angiogenic and anti-angiogenic mediators have been identified, one of t

177 Here, we examined how anti-angiogenic miR-221 and pro-angiogenic miR-130a affe

178 ectal cancer (CRC) patients treated with the anti-angiogenic molecule aflibercept, and the other for

179 down-regulation of CD36, a receptor for the anti-angiogenic molecule thrombospondin-1 (TSP-1).

180 ial to regulate the balance between pro- and anti-angiogenic molecules that influence the angiogenic

181 bioactive molecules, both growth factors and anti-angiogenic molecules.

182 Bevacizumab (Avastin(R)), an anti-angiogenic monoclonal antibody, has been used to de

183 Protein analysis identified an activation of anti-angiogenic mTOR effectors.

184 o produce two families of isoforms, pro- and anti-angiogenic, only the former of which is upregulated

185 MAD1/5/8 signalling results in both pro- and anti-angiogenic outputs, highlighting a poor understandi

186 ype 1 repeats were weakly inhibitory, but an anti-angiogenic peptide derived from this domain potentl

187 We report the protein expression of anti-angiogenic peptides (thrombospondin-1, TSP-1; and e

188 CD36-binding domain of thrombospondin-1 and anti-angiogenic peptides derived from this domain failed

189 ascular endothelial growth factor (VEGF) and anti-angiogenic pigment epithelium derived factor (PEDF)

190 y actions and prohomeostatic bioactivity, is anti-angiogenic, promotes corneal nerve regeneration, an

191 The data suggest that SsnB may exert its anti-angiogenic properties in part by downregulating CCN

192 lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxe

193 nal fragment of collagen XVIII known for its anti-angiogenic properties, is associated with neurologi

194 in with well established neuroprotective and anti-angiogenic properties.

195 t in part underlie its immunosuppressive and anti-angiogenic properties.

196 the molecular mechanism responsible for its anti-angiogenic property is unclear.

197 ethylation and increased levels of sFLT1, an anti-angiogenic protein implicated in causing the matern

198 Soluble endoglin is an anti-angiogenic protein that is released from the placen

199 and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that co

200 in combination with a peptidomimetic of the anti-angiogenic protein thrombospondin-1 (TSP-1 PM).

201 investigate the association between a novel anti-angiogenic protein, FK506-binding protein like (FKB

202 s paper, we report that the expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is dow

203 and on endothelial cell surfaces to HKa, an anti-angiogenic protein.

204 hese findings demonstrate MDSC as a critical anti-angiogenic regulator during transplantation.

205 and Met inhibitors including cabozantinib in anti-angiogenic resistant RCC.

206 Knocking down endogenous Ets-1 simulated an anti-angiogenic response of the miR-200b mimic-transfect

207 dothelial cells (MVECs), for it to elicit an anti-angiogenic response.

208 The observed antiproliferative and anti-angiogenic responses to CX-4945 in tumor cells and

209 -positive patients first line), ramucirumab (anti-angiogenic second line), and nivolumab or pembroliz

210 There were also higher levels of anti-angiogenic sFlt expression in the muscle and plasma

211 inase MEK5 are the upstream mediators of the anti-angiogenic signal by the natural angiogenesis inhib

212 dulates the crucial balance between pro- and anti-angiogenic signaling by activin receptor-like kinas

213 These results reveal that anti-angiogenic signaling through CD47 is highly redunda

214 mainly a vascular disease, caused by excess anti-angiogenic signalling in the peripartum period.

215 d through complex crosstalk between pro- and anti-angiogenic signals.

216 ), hypoxia also stimulates the production of anti-angiogenic signals.

217 re-activity studies showed that a functional anti-angiogenic site is located in the C-terminal region

218 d in the C-terminal region, whereas a latent anti-angiogenic site, activated by cleavage of Q76-K77 b

219 In summary, quininib is a novel anti-angiogenic small-molecule CysLT receptor antagonist

220 to be a potent stimulator for switching the anti-angiogenic SMC phenotype to the pro-angiogenic phen

221 novel concept that synthetic SMC exhibits an anti-angiogenic SMC phenotype, whereas contractile SMC s

222 tch in the expression of VEGF165 towards the anti-angiogenic splice isoform, VEGF165b, was seen in PC

223 nding kinetics of the other two pro- and all anti-angiogenic splice variants are not known.

224 suggesting that patients might benefit from anti-angiogenic strategies in the adjuvant setting.

225 ic properties that influence the response to anti-angiogenic strategies.

226 Given its position as an anti-angiogenic target in the treatment of human disease

227 identification of other endothelium-specific anti-angiogenic targets relevant to a broad spectrum of

228 ent predicted adverse effects of a reference anti-angiogenic thalidomide analog, 5HPP-33, on in vitro

229 oparticle that can potentially be used as an anti-angiogenic therapeutic agent in ovarian cancer.

230 genesis as well as testing anti-invasive and anti-angiogenic therapeutic approaches.

231 The model is then utilized to simulate anti-angiogenic therapeutic interventions targeting VEGF

232 VEGF biologics that have been used in ocular anti-angiogenic therapeutic regimes.

233 ey angiogenic cytokine and a major target in anti-angiogenic therapeutic strategies.

234 rstanding of the mechanisms of resistance to anti-angiogenic therapies and better selection of patien

235 s they are critical sites for drug delivery, anti-angiogenic therapies and immunotherapy.

236 WHERE NEXT?: Although anti-angiogenic therapies are promising, the duration of

237 ch likely contribute to this remodeling, but anti-angiogenic therapies do not improve AML patient out

238 Anti-angiogenic therapies for cancer such as VEGF neutra

239 Anti-angiogenic therapies have generated significant int

240 rded as essential to this purpose, thus far, anti-angiogenic therapies have shown only modest efficac

241 tional models can be used to predict optimal anti-angiogenic therapies in combination with other ther

242 Combined neuroprotective and anti-angiogenic therapies may be required to treat Mulle

243 Moreover, anti-angiogenic therapies synergize with the first-line

244 gs provide strong implications for designing anti-angiogenic therapies that may differentially target

245 Anti-angiogenic therapies that target VEGF and the VEGF

246 are no effective treatments for patients on anti-angiogenic therapies whose tumours progress.

247 Anti-angiogenic therapies--which 'normalize' the abnorma

248 e efficacy of new therapeutic strategies and anti-angiogenic therapies.

249 (NPs) holds promise in molecular imaging and anti-angiogenic therapies.

250 naling that could serve as a basis for novel anti-angiogenic therapies.

251 rapeutic for use in combination with current anti-angiogenic therapies.

252 ibition and to suggest molecular targets for anti-angiogenic therapies.

253 anti-vascular endothelial growth factor and anti-angiogenic therapies.

254 esis regulation is needed to improve current anti-angiogenic therapies.

255 inically relevant mechanism of resistance to anti-angiogenic therapy and combined inhibition of angio

256 ing tissue stiffness improves the outcome of anti-angiogenic therapy and prolongs patient survival.

257 is and support the potential clinical use of anti-angiogenic therapy as a novel treatment modality fo

258 As an example, we demonstrate using VAI that anti-angiogenic therapy can improve microcirculation and

259 Current anti-angiogenic therapy for cancer is based mainly on in

260 al of low molecular weight heparin (LMWH) in anti-angiogenic therapy has been tempered by poor in viv

261 metastases, a setting in which results with anti-angiogenic therapy have been disappointing.

262 nts lacking stromal Cav-1 might benefit from anti-angiogenic therapy in addition to standard regimens

263 hese results have important implications for anti-angiogenic therapy in breast cancer patients.

264 for further investigation and modulation of anti-angiogenic therapy in GBM.

265 r the use of SRPK1 inhibition as a potential anti-angiogenic therapy in PCa.

266 Anti-angiogenic therapy might also lead to mobilisation

267 Resistance to anti-angiogenic therapy might implicate alternative pro-

268 A/FGF18 pathway may be a rational target for anti-angiogenic therapy of HCC.

269 is for individualized treatment decisions in anti-angiogenic therapy of neovascular AMD and perhaps o

270 provide significantly improved evaluation of anti-angiogenic therapy response as compared with conven

271 inhibition provides a novel opportunity for anti-angiogenic therapy to complement VEGF or VEGFR2 blo

272 d leaky tumour vasculature might also enable anti-angiogenic therapy to increase the efficacy of radi

273 their involvement in adaptive resistance to anti-angiogenic therapy via enhanced metastasis.

274 ed, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the

275 t transport in the external tissue (e.g., by anti-angiogenic therapy) increased tumor fragmentation m

276 atified by germline BRCA status and previous anti-angiogenic therapy, to receive olaparib capsules 40

277 rently being explored in clinical trials for anti-angiogenic therapy.

278 refractoriness found in cancers resistant to anti-angiogenic therapy.

279 ory strategies could improve the efficacy of anti-angiogenic therapy.

280 ogression and could be potential targets for anti-angiogenic therapy.

281 nts that mediate refractoriness of tumors to anti-angiogenic therapy.

282 on and growth, alone and in combination with anti-angiogenic therapy.

283 At least half of patients fail to respond to anti-angiogenic treatment and the response duration is v

284 Anti-angiogenic treatment is generally well tolerated bu

285 ct of oral anti-cancer drug delivery through anti-angiogenic treatment strategies.

286 or growth kinetics influence the response to anti-angiogenic treatment targeting VEGF.

287 c intervention that could complement current anti-angiogenic treatment.

288 accurately predicts the tumor's response to anti-angiogenic treatment.

289 Immunotherapies and anti-angiogenic treatments, which target the tumor-inter

290 rectal cancer patients who are responding to anti-angiogenic treatments.

291 favorable balance in pro-angiogenic BDNF and anti-angiogenic TSP-1/CD36.

292 SP1 with either full-length TSP1 or 3TSR, an anti-angiogenic TSP1 fragment, suppresses heightened vas

293 palliative effect for VEGF/VEGFR1-targeting anti-angiogenic tumor therapies.

294 ostic estimates and inverse correlation with anti-angiogenic tyrosine-kinase inhibition in comparison

295 rs 1, 2, and 3 and PDGF receptors like other anti-angiogenic tyrosine-kinase inhibitors approved for

296 These results suggest that the - A(165b) anti-angiogenic variant would preferentially bind VEGFR2

297 We further demonstrated that the anti-angiogenic variant, VEGF-A(165b) selectively prefer

298 scular disease, including VEGF-A(121) and an anti-angiogenic variant, VEGF-A(165b).

299 trations of angiogenic (VEGF-A, Ang1, Ang2), anti-angiogenic (VEGF-A165b ) and lymphangiogenic (VEGF-

300 eported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms.